ACCESSWIRE

Crown Electrokinetics

Share
Crown Electrokinetics Film Division Announces Leadership Changes

LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / Crown Electrokinetics Corp. (NASDAQ:CRKN) ("Crown" or the "Company"), a prominent leader in smart glass technology and fiber optic network construction, today announced significant changes in its leadership team to bolster its capabilities further and accelerate to product launch.

Effective July 8, 2024, Tim Koch, who co-founded Crown Electrokinetics and has served as its Chief Technology Officer since 2015, will transition to the role of Chief Innovation Officer. As the new Chief Innovation Officer, Tim will focus on delivering electrokinetic film to the market and enhancing the company's product portfolio.

"We are excited to see Tim take on this new role. His leadership and technical expertise are invaluable as we strive to meet our clients' needs, deliver our electrokinetic film to market, and push the boundaries of what our technology can achieve," said Sheldon Davis, President.

Robert Vandal will assume the position of Chief Technology Officer starting July 8, 2024. With over three decades of experience in product development, process development, and manufacturing operations, Vandal has spearheaded pivotal advancements in the glass industry. He recently served as the Senior Director of R&D at Guardian Glass LLC, contributing significantly to key developments such as tempered vacuum insulating glass. His leadership has led to numerous successful global product launches across various areas of the glass industry. His extensive expertise will be instrumental in advancing our Dynamic Tint™ technology to market, developing our manufacturing capability, and accelerating the launch of Crown Smart Inserts.

"I am thrilled to welcome Rob to our team," remarked Tim Koch. "His leadership and knowledge will undoubtedly accelerate the delivery of our products to market. Rob's expertise will be crucial as we continue to build on our recent successes. We expect he will play a pivotal role in ensuring our offering not only meets but exceeds the expectations of our customers."

"I am incredibly excited to join Crown Electrokinetics at such a pivotal moment. The opportunity to bring innovations such as Dynamic Tint™ technology to market is exciting. I look forward to leveraging my experience to help propel Crown towards achieving future value-creating milestones."

Francois Prouhet is set to join as the Director of Business Development on July 8, 2024. In this role, Prouhet will utilize his experience to develop Crown's go-to-market strategy, establish business partnerships, and provide support for day-to-day execution. He has previously held positions at Guardian Industries and Cars.com, where he gained expertise in decision support analytics, financial modeling, and developing go-to-market strategies.

Sheldon Davis added, "Having Francois and Rob on our team marks a significant step. Their diverse experience and mindsets are crucial as we accelerate our development and product launch."

In connection with new appointments and pursuant to the agreed-upon terms, Crown granted Mr. Vandal 6,667 RSU and Mr. Prouhet 2,334 RSU as an inducement equity award outside of Crown's 2022 Employee Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The vesting dates will be based on business milestones agreed to between employees and the Compensation Committee of the Board of Directors for Crown. These inducement awards were approved by Crown's Board of Directors (the "Board"), including a majority of the independent directors serving on the Board.

About Crown Electrokinetics

Crown is comprised of two divisions, Fiber Optics and Electrokinetics Film. The Electrokinetics Film division is a smart glass technology and the creator of our Smart Window Insert based on its patented electrokinetic film. Crown's Fiber Optics division is a builder of underground fiber optic networks as well as other utility infrastructure projects.

Safe Harbor Statement:

Statements in this news release may be "forward-looking statements". Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Crown Electrokinetic Corporation undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Crown Electrokinetics Contact:

IR Email: info@crownek.com

SOURCE: Crown Electrokinetics



View the original press release on accesswire.com

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESSWIRE

DK

Subscribe to releases from ACCESSWIRE

Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESSWIRE

Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release

During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h

Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release

WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and

BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release

VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth

ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release

TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on

Accurate Background Partnering with Konfir to Provide Fast, Secure Instant Employment Verification in the United Kingdom5.12.2024 09:15:00 CET | Press release

IRVINE, CA / ACCESSWIRE / December 5, 2024 / Accurate Background, headquartered in Irvine, CA, and the largest privately held and minority-owned global provider of compliant background checks, drug and health screening, and workforce monitoring solutions, has announced a new partnership with Konfir, an innovative company providing employment verification technology in the UK. This collaboration will provide Accurate's clients access to Konfir's real-time verification tools via Accurate technology. Accurate's integration of Konfir's instant employment verification API will allow candidates to aggregate real-time data from multiple data sources including Payroll, HMRC, and Open Banking, streamlining screening processes and reducing time-to-hire. In addition, Accurate will now offer enhanced fraud mitigation tools through Konfir's suite of insights helping employers identify potential hiring risks more effectively. Kevin Stone, Sales & Marketing Director at Accurate, commented: "At Accura

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye